BCHT(SH:688276)2024-03-19 16:00Financial Performance - The proposed cash dividend for 2023 is CNY 1.50 per 10 shares, totaling CNY 61,926,104.70, which represents 12.36% of the net profit attributable to shareholders[6]. - The company has not achieved profitability since its listing[4]. - The company's operating revenue for 2023 reached ¥1,824,688,777.32, representing a 70.30% increase compared to ¥1,071,446,025.21 in 2022[23]. - Net profit attributable to shareholders for 2023 was ¥501,009,182.39, a significant increase of 175.98% from ¥181,536,723.75 in the previous year[23]. - The net profit after deducting non-recurring gains and losses was ¥493,358,270.16, up 195.86% from ¥166,753,980.61 in 2022[23]. - The net cash flow from operating activities for 2023 was ¥255,206,956.72, a remarkable increase of 540.93% compared to ¥39,818,408.14 in 2022[23]. - As of the end of 2023, the net assets attributable to shareholders were ¥4,020,361,575.99, reflecting a 12.95% increase from ¥3,559,536,200.04 at the end of 2022[23]. - Total assets at the end of 2023 amounted to ¥5,046,237,662.74, which is a 17.80% increase from ¥4,283,551,750.23 in 2022[23]. - The basic earnings per share increased by 175.00% to RMB 1.21, while the diluted earnings per share also rose by 175.00% to RMB 1.21[25]. - The gross profit margin for the main business was 90.24%, an increase of 3.05 percentage points year-on-year[79]. Research and Development - The company invested CNY 198.74 million in R&D, accounting for 10.89% of its revenue during the reporting period[33]. - The company has 16 ongoing research projects, with 6 projects approved for clinical trials or registration applications[33]. - The company is preparing for the III phase clinical trial of the acellular pertussis vaccine, which has completed the I phase trial[40]. - The company has established five core technology platforms for vaccine development, including "viral large-scale culture technology platform" and "mRNA vaccine technology platform" to enhance its core competitiveness[41]. - The company has a research and development team of 134 people, accounting for 10.80% of the total workforce, with an average salary of ¥22.13 million, up from ¥14.82 million in the previous period[57]. - The total R&D investment for the year was approximately ¥198.74 million, an increase of 27.58% compared to the previous year, with R&D expenses accounting for 10.89% of operating income[53]. - The company has filed for 5 invention patents during the reporting period, bringing the total to 81 applications and 47 granted patents[52]. - The company is focusing on R&D investment and market expansion, with a diverse pipeline of vaccines and monoclonal antibody products targeting both children and adults[46]. Market and Sales Strategy - The company launched a new shingles vaccine, breaking the import monopoly in the domestic market and becoming a new profit growth point[32]. - The company is enhancing its marketing strategy and digital marketing efforts to expand product awareness and influence in a declining newborn birth rate environment[34]. - The domestic sales strategy employs a direct sales model, while international sales are conducted through distributors, covering all provinces in China except Hong Kong, Macau, and Taiwan[41]. - The company achieved a significant increase in export sales of the varicella vaccine, marking its first export to Ghana and signing a cooperation agreement with Russia[35]. - The company plans to accelerate the internationalization of its existing products while enhancing domestic market marketing efforts[127]. Environmental Compliance - The company has implemented a self-monitoring plan to ensure compliance with pollution discharge standards, with quarterly reports submitted to the national pollution discharge permit management information platform[200]. - The company’s wastewater discharge for ammonia nitrogen was reported at 0.43 mg/L, well below the limit of 1 mg/L, demonstrating effective treatment processes[188]. - The company’s emissions of sulfur dioxide and nitrogen oxides from the gas discharge are compliant with the respective limits of 50 mg/m³ and 200 mg/m³[186]. - The company has received environmental impact report approvals for multiple vaccine production projects, including a project for an annual output of 20 million doses of varicella and herpes zoster vaccines, which was completed on December 19, 2023[6]. - The company emphasizes a commitment to green, environmentally friendly, low-carbon, and sustainable development practices[198]. Corporate Governance - All board members attended the board meeting[5]. - The board of directors has established four specialized committees to enhance decision-making objectivity and governance[131]. - The company held two shareholder meetings during the reporting period, with all proposed resolutions being approved without any rejections[134]. - The company has maintained a stable management team with no significant turnover in key positions[137]. - The company is committed to maintaining transparency and accountability in its financial reporting practices[138]. Future Outlook - The company expects a revenue growth guidance of 10-12% for the next fiscal year[141]. - The company plans to conduct clinical trial applications for several vaccines in 2024, including adjuvanted influenza vaccine and recombinant shingles vaccine[99]. - The company aims to improve operational efficiency and increase profitability through strategic initiatives[138]. - Future guidance indicates a focus on enhancing technological capabilities and exploring potential mergers and acquisitions[138].